May 28, 2014 at 6 pm CEST (Rome) - Topic Chemotherapy for Advanced NSCLC: State-of-the-Art in 2014 - The European Perspective
June 23, 2014 at 8 pm EDT - Topic: Biomarkers and Personalized Medicine for Patients with Lung Cancer
The International Association for the Study of Lung Cancer (IASLC) is disappointed in the recommendations made by the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to not support Medicare coverage of low-dose computed tomography (LDCT) screening of patients at high risk for lung cancer.
Spotlight on KRAS Mutant Lung Cancer
Werner H. Kirsten was a young pathologist working at the University of Chicago. He noted with interest that he could transmit leukemia to rats with cell free extract obtained from leukemic mice, which suggested the presence of a microscopic transmitting agent such as a virus.